Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

6.415 -0.225 (-3.39%)

Delayed Quote Updated: 12:56 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021

October 21, 2021

From Precision BioSciences, Inc.

Via Business Wire

The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review ↗

October 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19...

Via Benzinga

Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)

September 27, 2021

From Precision BioSciences, Inc.

Via Business Wire

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer

September 27, 2021

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 10, 2021

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences, iECURE Ink Licensing Pact For Gene Editing Therapies ↗

September 09, 2021

Precision BioSciences Inc (NASDAQ: DTIL) and iECURE announced a license and collaboration agreement. Under the agreement iECURE plans to advance Precision's PBGENE-...

Via Benzinga

Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline

September 09, 2021

From Precision BioSciences, Inc.

Via Business Wire

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗

September 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...

Via Benzinga

Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies

September 09, 2021

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications ↗

September 02, 2021

Precision BioSciences Inc (NASDAQ: DTIL) and Tiziana Life Sciences plc (NASDAQ: TLSA) have announced an exclusive license agreement for Tiziana's...

Via Benzinga

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab ↗

September 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...

Via Benzinga

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

September 02, 2021

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021

August 25, 2021

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences: Q2 Earnings Insights ↗

August 12, 2021

Shares of Precision BioSciences (NASDAQ:DTIL) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 157.14% year...

Via Benzinga

Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update

August 12, 2021

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021

August 05, 2021

From Precision BioSciences, Inc.

Via Business Wire

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy ↗

July 01, 2021

Precision BioSciences Inc (NASDAQ: DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin...

Via Benzinga

Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma

July 01, 2021

From Precision BioSciences, Inc.

Via Business Wire

44 Stocks Moving In Monday's Mid-Day Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...

Via Benzinga

60 Biggest Movers From Yesterday ↗

June 29, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...

Via Benzinga

Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial ↗

June 28, 2021

Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision...

Via Benzinga

Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma

June 28, 2021

From Precision BioSciences, Inc.

Via Business Wire

24 Stocks Moving in Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim...

Via Benzinga

Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma

June 04, 2021

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

June 01, 2021

From Precision BioSciences, Inc.

Via Business Wire

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗

May 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...

Via Benzinga

Precision BioSciences Appoints Alex Kelly as Chief Financial Officer

May 27, 2021

From Precision BioSciences, Inc.

Via Business Wire

Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference

May 26, 2021

From Precision BioSciences Inc.

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.